ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2636

Understanding Why Treat-to-Target Strategies Are Difficult to Follow

Liana Fraenkel1, Meaghan Cunningham2 and Paul Falzer3, 1Medicine, Section of Rheumatology, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, 2Medicine, Yale University School of Medicine, New Haven, CT, 3Medicine, VA Connecticut Healthcare System, New Haven, CT

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: DMARDs and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research V: Rheumatoid Arthritis Management in the Treat-to-Target Era

Session Type: Abstract Submissions (ACR)

Background/Purpose: Treat-to-target (T2T) refers to a set of decision strategies widely advocated for the optimal management of rheumatoid arthritis (RA). Despite considerable evidence that this approach leads to improved outcomes, T2T strategies are not consistently adopted. We hypothesize that patients’ experience of illness complicates the decision to adjust treatment when indicated by recommended thresholds. While disease activity thresholds assess a single reference point (current level of disease activity), patients’ appraisal of their illness depends on multiple reference points. Therefore, in addition to current experience, we also examine past and future reference points, i.e., how current illness compares with recalled past experience and the difference between current and expected future health states.

Methods: We conducted a prospective, repeated measures study in which 142 RA patients (mean age: 59, 86% female) were interviewed at baseline, 2, 4, and 6 months. Disease activity was measured using the RAPID-4. Patients’ current experience was measured using current (8-item Brief Illness Perception Questionnaire), past (recent change in illness severity measured on a 5-point Likert scale) and future (discrepancy between the patient’s current and desirable health states measured on an 11-point numeric rating scale) reference points. We used generalized estimating equations to examine illness perception items, recent change, and discrepancy as main effects and in combination with disease in predicting treatment adjustment. Models are adjusted for age, education, income, duration, and biologic use.

Results: We found that disease activity, three illness perception factors: illness consequences, concern, emotional impact and both past and future reference points predict future treatment adjustments. These illness experience factors are also significant as interactions and the interaction model provided a slightly better fit (QICC index) than the main effects model indicating that the combination of disease activity and the three temporal reference points predicts future treatment adjustments better than disease activity alone.

Conclusion: These findings indicate that recommended T2T thresholds may not adequately reflect thresholds used clinical practice. Physicians likely take patient experience of their illness into account in making treatment recommendations, making it more difficult to consistently adhere to T2T thresholds. Understanding the factors that impact on decision making, may help modify T2T strategies to improve their uptake and ultimately improve patient outcomes.


Disclosure:

L. Fraenkel,
None;

M. Cunningham,
None;

P. Falzer,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/understanding-why-treat-to-target-strategies-are-difficult-to-follow/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology